[1]
|
Barzaman, K., Karami, J., Zarei, Z., Hosseinzadeh, A., Kazemi, M.H., Moradi-Kalbolandi, S., et al. (2020) Breast Cancer: Biology, Biomarkers, and Treatments. International Immunopharmacology, 84, Article 106535. https://doi.org/10.1016/j.intimp.2020.106535
|
[2]
|
Shien, T. and Iwata, H. (2020) Adjuvant and Neoadjuvant Therapy for Breast Cancer. Japanese Journal of Clinical Oncology, 50, 225-229. https://doi.org/10.1093/jjco/hyz213
|
[3]
|
Zhang, J., Wu, Y., Li, Y., Li, S., Liu, J., Yang, X., et al. (2024) Natural Products and Derivatives for Breast Cancer Treatment: From Drug Discovery to Molecular Mechanism. Phytomedicine, 129, Article 155600. https://doi.org/10.1016/j.phymed.2024.155600
|
[4]
|
Carey, L.A. and Sharpless, N.E. (2011) Parp and Cancer—If It’s Broke, Don’t Fix It. New England Journal of Medicine, 364, 277-279. https://doi.org/10.1056/nejme1012546
|
[5]
|
Boughey, J.C., McCall, L.M., Ballman, K.V., Mittendorf, E.A., Ahrendt, G.M., Wilke, L.G., et al. (2014) Tumor Biology Correlates with Rates of Breast-Conserving Surgery and Pathologic Complete Response after Neoadjuvant Chemotherapy for Breast Cancer. Annals of Surgery, 260, 608-616. https://doi.org/10.1097/sla.0000000000000924
|
[6]
|
Takada, M. and Toi, M. (2020) Neoadjuvant Treatment for HER2-Positive Breast Cancer. Chinese Clinical Oncology, 9, 32-32. https://doi.org/10.21037/cco-20-123
|
[7]
|
Morrow, M. (2018) Management of the Node-Positive Axilla in Breast Cancer in 2017. JAMA Oncology, 4, 250-251. https://doi.org/10.1001/jamaoncol.2017.3625
|
[8]
|
Villacampa, G., Tung, N.M., Pernas, S., Paré, L., Bueno-Muiño, C., Echavarría, I., et al. (2023) Association of HER2DX with Pathological Complete Response and Survival Outcomes in HER2-Positive Breast Cancer. Annals of Oncology, 34, 783-795. https://doi.org/10.1016/j.annonc.2023.05.012
|
[9]
|
Cheng, Y., Xiang, H., Xin, L., Duan, X. and Liu, Y. (2022) Neoadjuvant Therapy for Early Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer in China: A Multicenter Real-World Study (CSBrS-015). Chinese Medical Journal, 135, 2311-2318. https://doi.org/10.1097/cm9.0000000000002197
|
[10]
|
Zhou, M., Wang, S., Wan, N., Yuan, S., Hu, X., Zhou, W., et al. (2022) Efficacy and Safety of Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Chemotherapy Regimen in Chinese Patients with HER2-Positive Early Breast Cancer: A Real-World Retrospective Multi-Center Cohort Study. Annals of Translational Medicine, 10, 1387-1387. https://doi.org/10.21037/atm-22-6054
|
[11]
|
Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., et al. (2009) New Response Evaluation Criteria in Solid Tumours: Revised Recist Guideline (Version 1.1). European Journal of Cancer, 45, 228-247. https://doi.org/10.1016/j.ejca.2008.10.026
|
[12]
|
Choi, W.J., Kim, H.H., Cha, J.H., Shin, H.J. and Chae, E.Y. (2019) Comparison of Pathologic Response Evaluation Systems after Neoadjuvant Chemotherapy in Breast Cancers: Correlation with Computer-Aided Diagnosis of MRI Features. American Journal of Roentgenology, 213, 944-952. https://doi.org/10.2214/ajr.18.21016
|
[13]
|
You, C., Li, J., Zhi, W., Chen, Y., Yang, W., Gu, Y., et al. (2019) The Volumetric-Tumour Histogram-Based Analysis of Intravoxel Incoherent Motion and Non-Gaussian Diffusion MRI: Association with Prognostic Factors in HER2-Positive Breast Cancer. Journal of Translational Medicine, 17, Article No. 182. https://doi.org/10.1186/s12967-019-1911-6
|
[14]
|
Negrão, E.M.S., Souza, J.A., Marques, E.F. and Bitencourt, A.G.V. (2019) Breast Cancer Phenotype Influences MRI Response Evaluation after Neoadjuvant Chemotherapy. European Journal of Radiology, 120, Article 108701. https://doi.org/10.1016/j.ejrad.2019.108701
|
[15]
|
Zhang, X., Wang, D., Liu, Z., Wang, Z., Li, Q., Xu, H., et al. (2020) The Diagnostic Accuracy of Magnetic Resonance Imaging in Predicting Pathologic Complete Response after Neoadjuvant Chemotherapy in Patients with Different Molecular Subtypes of Breast Cancer. Quantitative Imaging in Medicine and Surgery, 10, 197-210. https://doi.org/10.21037/qims.2019.11.16
|
[16]
|
Chen, S., Liang, Y., Feng, Z. and Wang, M. (2019) Efficacy and Safety of HER2 Inhibitors in Combination with or without Pertuzumab for HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis. BMC Cancer, 19, Article No. 973. https://doi.org/10.1186/s12885-019-6132-0
|
[17]
|
Nahta, R., Hung, M. and Esteva, F.J. (2004) The Her-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells. Cancer Research, 64, 2343-2346. https://doi.org/10.1158/0008-5472.can-03-3856
|
[18]
|
Guthrie, G.J.K., Charles, K.A., Roxburgh, C.S.D., Horgan, P.G., McMillan, D.C. and Clarke, S.J. (2013) The Systemic Inflammation-Based Neutrophil-Lymphocyte Ratio: Experience in Patients with Cancer. Critical Reviews in Oncology/Hematology, 88, 218-230. https://doi.org/10.1016/j.critrevonc.2013.03.010
|
[19]
|
Noh, H., Eomm, M. and Han, A. (2013) Usefulness of Pretreatment Neutrophil to Lymphocyte Ratio in Predicting Disease-Specific Survival in Breast Cancer Patients. Journal of Breast Cancer, 16, 55-59.
|
[20]
|
Ding, N., Huang, J., Li, N., Yuan, J., Wang, S. and Xiao, Z. (2020) Roles of Neutrophil/Lymphocyte Ratio in Prognosis and in Differentiation of Potential Beneficiaries in HER2-Positive Breast Cancer with Trastuzumab Therapy. BMC Cancer, 20, Article No. 235. https://doi.org/10.1186/s12885-020-06750-3
|
[21]
|
Ulas, A., Avci, N., Kos, T., Cubukcu, E., Olmez, O.F., Bulut, N. and Degirmenci, M. (2015) Are Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio Associated with Prognosis in Patients with HER2-Positive Early Breast Cancer Receiving Adjuvant Trastuzumab? Journal of B.U.ON., 20, 714-722.
|
[22]
|
Ding, N., Pang, J., Liu, X., He, X., Zhou, W., Xie, H., et al. (2024) Prognostic Value of Baseline Neutrophil/Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer: Exploratory Analysis of Data from the Cleopatra Trial. Breast Cancer Research, 26, Article No. 9. https://doi.org/10.1186/s13058-023-01761-x
|
[23]
|
Litton, J.K., Gonzalez-Angulo, A.M., Warneke, C.L., Buzdar, A.U., Kau, S., Bondy, M., et al. (2008) Relationship between Obesity and Pathologic Response to Neoadjuvant Chemotherapy among Women with Operable Breast Cancer. Journal of Clinical Oncology, 26, 4072-4077. https://doi.org/10.1200/jco.2007.14.4527
|
[24]
|
Krystel-Whittemore, M., Xu, J., Brogi, E., Ventura, K., Patil, S., Ross, D.S., et al. (2019) Pathologic Complete Response Rate According to HER2 Detection Methods in HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy. Breast Cancer Research and Treatment, 177, 61-66. https://doi.org/10.1007/s10549-019-05295-9
|
[25]
|
Wang, Y., Singh, K., Dizon, D., Graves, T., Amin, A. and Yakirevich, E. (2021) Immunohistochemical HER2 Score Correlates with Response to Neoadjuvant Chemotherapy in HER2-Positive Primary Breast Cancer. Breast Cancer Research and Treatment, 186, 667-676. https://doi.org/10.1007/s10549-021-06124-8
|
[26]
|
Sánchez-Muñoz, A., Navarro-Perez, V., Plata-Fernández, Y., Santonja, A., Moreno, I., Ribelles, N., et al. (2015) Proliferation Determined by Ki-67 Defines Different Pathologic Response to Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer. Clinical Breast Cancer, 15, 343-347. https://doi.org/10.1016/j.clbc.2015.01.005
|
[27]
|
Kurozumi, S., Inoue, K., Takei, H., Matsumoto, H., Kurosumi, M., Horiguchi, J., et al. (2015) ER, PgR, Ki67, P27kip1, and Histological Grade as Predictors of Pathological Complete Response in Patients with HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy Using Taxanes Followed by Fluorouracil, Epirubicin, and Cyclophosphamide Concomitant with Trastuzumab. BMC Cancer, 15, Article No. 622. https://doi.org/10.1186/s12885-015-1641-y
|